Table 5.
Most common treatment-related adverse events occurring in ≥5 % of patients
| Treatment-related adverse events | Patients, n (%) | |||||
|---|---|---|---|---|---|---|
| Exemestane (n = 149) | Anastrozole (n = 149) | |||||
| Grade | Grade | |||||
| Any | 1–2 | 3–5 | Any | 1–2 | 3–5 | |
| Hot flush | 33 (22) | 33 (22) | 0 | 22 (15) | 22 (15) | 0 |
| Arthralgia | 25 (17) | 24 (16) | 1 (1) | 25 (17) | 25 (17) | 0 |
| Musculoskeletal stiffness | 17 (11) | 17 (11) | 0 | 11 (7) | 11 (7) | 0 |
| GGT increased | 15 (10) | 11 (7) | 4 (3) | 5 (3) | 4 (3) | 1 (1) |
| Hypoesthesia | 12 (8) | 12 (8) | 0 | 9 (6) | 9 (6) | 0 |
| Body weight increased | 11 (7) | 11 (7) | 0 | 5 (3) | 5 (3) | 0 |
| ALP increased | 9 (6) | 9 (6) | 0 | 5 (3) | 5 (3) | 0 |
| Decreased appetite | 9 (6) | 8 (5) | 1 (1) | 6 (4) | 6 (4) | 0 |
| Fatigue | 8 (5) | 8 (5) | 0 | 2 (1) | 2 (1) | 0 |
| Hypertension | 8 (5) | 7 (5) | 1 (1) | 10 (7) | 8 (5) | 2 (1) |